Presidential Lectureship | Viral Infections in Hematopoietic Cell Transplantation (HCT) - Lifetime Journey
Clinicians need to stay abreast of the changing epidemiology of viral infections like COVID19 and the impact on the incidence of other respiratory infections, as well as the updates in testing for CMV and newly published guidelines. It is imperative to stay abreast of the changing risk factors in HCT patients based on the type of cancer, evolving treatments for Hematopoietic Cell Transplantation (HCT) conditioning chemotherapy, post-transplant GVHD care that leads to varying level of immunosuppression and opportunistic viral infection/reactivation.
A review and update from a leading authority in the field will describe the evolution of knowledge surrounding viral infections; CMV, respiratory infections, diagnostic testing, while referencing updated CMV guidelines, and vaccination in HCT. This lecture will explore the promises and challenges in immunocompromised patients, allowing for time update on viral infections in HCT with a historical background, which will better equip the clinician to treat the patient, resulting in better outcomes.
Target Audience
Clinicians who treat and care for hematopoietic cell transplant patients.
Learning Objectives
- Demonstrate epidemiology of respiratory viral infections in Hematopoietic Cell Transplantation (HCT).
- Outline the refractory/resistant CMV in HCT.
- Examine the role of vaccination in HCT to prevent viral infections.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Per Ljungman, MD, PhD Professor Emeritus, Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Department of Medicine Huddinge, Karolinska Institute
Presenter: Dr. Ljungman has indicated the following relevant financial relationships: Consultant for Moderna and Takeda; Grant/Research Support from Allovir; and On the Speakers Bureau for MSD.
Planner: Dr. Sanjeet Singh Dadwal, MD has indicated the following relevant financial relationships: Consultant for Merck and Takeda; Grant/Research Support from Allovir, Ansun Biopharma, and Geovax; On the Speakers Bureau for Astellas and Takeda.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Presidential Lectureship | Viral Infections in Hematopoietic Cell Transplantation (HCT) - Lifetime Journey for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance